Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2003
10/23/2003WO2003087061A1 Pyrazole compounds as anti-inflammatory and analgesic agents
10/23/2003WO2003087019A1 Hyaluronic acid modification product
10/23/2003WO2003086459A1 Methods of treatement using ctla-4 antibodies
10/23/2003WO2003086458A1 Recombinant anti-interleukin-9 antibodies
10/23/2003WO2003086415A1 Method for inhibiting bone resorption with an alendronate and vitamin d formulation
10/23/2003WO2003086400A1 N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis
10/23/2003WO2003086396A1 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
10/23/2003WO2003086390A1 Imidazole compounds as anti-inflammatory and analgesic agents
10/23/2003WO2003086386A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
10/23/2003WO2003086385A1 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
10/23/2003WO2003086380A1 Ptx3 gene expression suppressing method
10/23/2003WO2003086373A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003WO2003086355A1 Novel polymorphs and pseudopolymorphs of risedronate sodium
10/23/2003WO2003086326A2 G-type peptides to ameliorate atherosclerosis
10/23/2003WO2003086325A2 Cyanamides useful as reversible inhibitors of cysteine proteases
10/23/2003WO2003086317A2 Protein a compositions and methods of use
10/23/2003WO2003086315A2 Tyrosine kinase inhibitors
10/23/2003WO2003086314A2 Tyrosine kinase inhibitors
10/23/2003WO2003086311A2 Methods for treating tweak-related conditions
10/23/2003WO2003086309A2 NF-κB INHIBITORS
10/23/2003WO2003086294A2 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
10/23/2003WO2003086289A2 Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
10/23/2003WO2003086282A2 Nitric oxide donors, compositions and methods of use
10/23/2003WO2003057252A8 Human mast cell-expressed membrane proteins
10/23/2003WO2003057147A3 Useful aroyl pyrrole heteroaryl methanones and methanols
10/23/2003WO2003039473A3 Method for treating or preventing inflammatory diseases
10/23/2003WO2003029410A3 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER
10/23/2003WO2003007954A3 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
10/23/2003WO2002092015A3 Reagents and methods for modulating dkk-mediated interactions
10/23/2003WO2002081521A8 Osteoprotegerin in milk
10/23/2003WO2002066494A8 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
10/23/2003WO2002060535A8 Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
10/23/2003WO2002046384A3 Kinases and phosphatases sequences, and use thereof
10/23/2003WO2001009328A8 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
10/23/2003WO2001002567A8 16405 receptor, a g-protein coupled receptor
10/23/2003WO2001000812A8 22012, a novel human carboxypeptidase
10/23/2003US20030199701 Treating under hydrolyzing conditions a hydantoin compound to form an alpha-amino acid derivative
10/23/2003US20030199679 Recombinant antibodies specific for TNF-alpha
10/23/2003US20030199673 For inducing immune response and administering immunotherapy
10/23/2003US20030199567 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
10/23/2003US20030199563 Heterocyclic containing biphenyl aP2 inhibitors and method
10/23/2003US20030199562 Substituted benzoxazoles as estrogenic agents
10/23/2003US20030199561 Boronic ester and acid compounds, synthesis and uses
10/23/2003US20030199548 Administering quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives containing one of the ring selected from benzene, pyridine, thienyl, furanyl, imidazolyl and triazolyl for therapy in pain management
10/23/2003US20030199534 Kinase inhibitors
10/23/2003US20030199525 Kinase inhibitors
10/23/2003US20030199510 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
10/23/2003US20030199506 An enzyme inhibitor of cysteine proteases, a morpholine-4-carboxyamide 1,3,4-oxadiazole derivatives; for treating arthritis, muscular dystrophy, inflammation, tumor, glomerulonephritis, malaria, periodontal disease
10/23/2003US20030199502 Indoloquinazolinones
10/23/2003US20030199501 A sulfonylamino-tetrahydro(1,3)thiazolo(5,4-c)pyridinyl or benzothiazole derivatives, for treating diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia
10/23/2003US20030199498 Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
10/23/2003US20030199497 Novel calcium receptor active molecules and method for preparing same
10/23/2003US20030199482 Anticholesterol agents; a drug mixture for treating hypercholesterolemia comprising an apical sodium co-dependent bile acid transport inhibitor, enzyme inhibitors of a cyclooxygenase-2
10/23/2003US20030199479 Oxa(thia)zolidine derivative and anti-inflammatory drug
10/23/2003US20030199478 For modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation
10/23/2003US20030199103 Novel amino acid sequences for human epidermal growth factor-like polypeptides
10/23/2003US20030199043 Therapeutic proteins (including polypeptide, antibody, peptide or fragment or variants)fused to albumin or fragment or variant linked by a linker peptide; nonglycosylated
10/23/2003US20030199042 Novel morphogenic protein
10/23/2003US20030198975 Proteins associated with cell growth, differentiation, and death
10/23/2003US20030198691 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
10/23/2003DE20310493U1 Micronutrient combination product for dietetic treatment of inflammatory-rheumatic diseases and osteoporosis, containing specific amounts of several vitamins, minerals, trace elements and antioxidants
10/23/2003CA2482718A1 Derivatives of the il-2 receptor gamma chain, their production and use
10/23/2003CA2482634A1 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signal transduction
10/23/2003CA2482387A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use
10/23/2003CA2482382A1 Pyrazole compounds as anti-inflammatory and analgesic agents
10/23/2003CA2481855A1 Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
10/23/2003CA2481747A1 Recombinant anti-interleukin-9 antibodies
10/23/2003CA2481532A1 Imidazole compounds as anti-inflammatory and analgesic agents
10/23/2003CA2481387A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003CA2481372A1 Method to inhibit cell growth using oligonucleotides
10/23/2003CA2481320A1 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
10/23/2003CA2481282A1 Protein a compositions and methods of use
10/23/2003CA2481207A1 Methods of treatment using ctla-4 antibodies
10/23/2003CA2481178A1 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
10/23/2003CA2481074A1 Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
10/23/2003CA2480832A1 Nitric oxide donors, compositions and methods of use
10/23/2003CA2480814A1 Method for inhibiting bone resorption with an alendronate and vitamin d formulation
10/23/2003CA2480764A1 Novel polymorphs and pseudopolymorphs of resedronate sodium
10/23/2003CA2480758A1 Tyrosine kinase inhibitors
10/23/2003CA2480754A1 Tyrosine kinase inhibitors
10/23/2003CA2480745A1 Methods for treating tweak-related conditions
10/23/2003CA2480217A1 G-type peptides to ameliorate atherosclerosis
10/23/2003CA2478392A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
10/23/2003CA2477692A1 Cyanamides useful as reversible inhibitors of cysteine proteases
10/22/2003EP1355152A1 Compositions for diagnosis and therapy of diseases associated with aberrant expression of kremen
10/22/2003EP1354953A1 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/22/2003EP1354949A1 Human fgf23 protein mutant lowering blood phosphorus level
10/22/2003EP1354947A1 Novel polypeptide
10/22/2003EP1354891A1 Medicament comprising NK4 gene or recombinant NK4 protein
10/22/2003EP1354888A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines
10/22/2003EP1354884A1 Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
10/22/2003EP1354882A1 Dipeptidyl peptidase iv inhibitor
10/22/2003EP1354603A1 Concomitant drugs
10/22/2003EP1354598A2 Therapeutic uses of BR43X2 soluble receptors
10/22/2003EP1354595A1 Composition containing extracts of butyrospermum parkii and its use as medicament or dietary supplement
10/22/2003EP1354590A1 Drugs against articular failure
10/22/2003EP1354584A1 Preventives for arthritis
10/22/2003EP1354208A2 Methods of diagnosis and treatment of osteoporosis
10/22/2003EP1354047A2 Methods for screening compounds that modulate lipid metabolism
10/22/2003EP1353955A2 High affinity antibodies
1 ... 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 ... 820